RAKESH AMIN: Open Payments
NPI 1437445475 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$878,924 in 999 payments from 14 companies in 2025. Trend: 2023 $547,482 · 2024 $734,674 · 2025 $878,924
Speaker / faculty: $558,337Travel & lodging: $133,971Honoraria: $105,500Consulting: $57,604Food & beverage: $23,512
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 177 | $167,198 |
| Alkermes, Inc. | 175 | $151,970 |
| Axsome Therapeutics, Inc. | 141 | $131,836 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 136 | $121,553 |
| E.R. Squibb & Sons, L.L.C. | 130 | $120,215 |
| Otsuka America Pharmaceutical, Inc. | 110 | $75,857 |
| Janssen Pharmaceuticals, Inc | 75 | $57,901 |
| ABBVIE INC. | 40 | $49,648 |
| Janssen Scientific Affairs, LLC | 1 | $1,500 |
| Teva Pharmaceuticals USA, Inc. | 6 | $623 |
Products named: INGREZZA, Auvelity, CAPLYTA, LYBALVI, COBENFY, REXULTI, SPRAVATO, VRAYLAR.
Industry payments across TN — which companies pay providers there.
